Single-course specific immunotherapy with mixed pollen allergoids: results of a multi-centre study.
BACKGROUND
A short-term immunotherapy vaccine for the treatment of pollen allergy has been developed utilising L-tyrosine adsorbed allergoids. The reduced number of injections could provide advantages over long-term therapy schedules. This would improve compliance and support application of specific immunotherapy (SIT) to a greater extent. We report a multicenter study to evaluate the efficacy and safety of this treatment in a clinical practice setting.


METHODS
Patients (n = 1808) with a diagnosis of sensitivities to various pollens and symptoms of allergic asthma and/or allergic rhinitis and/or allergic conjunctivitis were selected. The vaccine formulation was made up according to individual sensitivities and contained L-tyrosine adsorbed allergoids. The patients were treated with a 3-injection initial course followed by a 3-injection maintenance course. Efficacy was measured by consumption of symptomatic anti-allergic medication compared with that in the previous season and by physician assessment using a 5-point scale. All adverse events were recorded.


RESULTS
Efficacy was demonstrated by a considerable decrease in regular and frequent use of medication compared with that in the previous season (p < 0.001). In addition, in 80 % of the patients, the physician's assessment was either "good" or "very good". These outcomes were unaffected by the closeness of the treatment course to the onset of the pollen season. Tolerability was good and most local and systemic reactions were mild.


CONCLUSIONS
The treatment of pollen-allergic patients with a short-term SIT using a 6-injection pollen allergoid/L-tyrosine vaccine in a clinical practice setting provided a high level of efficacy with a low incidence of mainly mild adverse events.
Drachenberg
K J
KJ
Bencard Allergie GmbH, Munich, Germany.
Pröll
S
S
Urban
E
E
Woroniecki
S R
SR
D000293:Adolescent; D000327:Adsorption; D000328:Adult; D000485:Allergens / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D002648:Child; D003233:Conjunctivitis, Allergic / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D010352:Patient Dropouts; D006109:Poaceae; D011058:Pollen / Q000009:adverse effects*; D006255:Rhinitis, Allergic, Seasonal / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D012449:Safety; D016896:Treatment Outcome; D014197:Trees; D014443:Tyrosine
D000485:Allergens; D014443:Tyrosine